Compare Airbnb, Inc. (ABNB) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Airbnb, Inc. vs BioNTech SE - ADR — how do they compare? Airbnb, Inc. trades at $143.13 (market cap $88.31B), while BioNTech SE - ADR trades at $93.11 (market cap $23.84B). The key difference: Airbnb, Inc. is far larger — about 3.7× BioNTech SE - ADR's market cap, and Airbnb, Inc. is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ABNB | BNTX | |
|---|---|---|
Market Cap | $88.31B | $23.84B |
Sector | Consumer Cyclical | Health |
52-Week High | $148.93 | $119.34 |
52-Week Low | $111.54 | $83.89 |
Enterprise Value | $78.84B | $7.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) trades at $148.80, showing minimal daily movement with a slight decline of 0.09%. The stock maintains a bullish technical outlook with strong moving average signals and trades near pivot point resistance at $149. Fundamentally, the company demonstrates robust profitability with 82.9% gross margins and 19.9% net income margin, though recent quarters have seen earnings misses against expectations. Revenue growth continues with 2025 reaching $12.24 billion, supported by the company's asset-light model and global travel recovery.
The investment case balances strong fundamentals against valuation concerns, with a P/E of 36.5 suggesting premium pricing. Analyst consensus remains positive with a $161.80 price target, though recent earnings misses and CEO stock sales warrant monitoring. Key risks include travel demand sensitivity, competitive pressures, and execution of new initiatives like hotel expansion and AI development. The stock offers growth exposure to travel recovery but requires careful valuation assessment.
BioNTech (BNTX) trades at $94.29, down 3.34% on the day, as the company navigates its transition from COVID-19 vaccine dominance to oncology focus. The stock shows a bullish technical signal with strong analyst support (87.5% buy ratings) and a $130.83 consensus price target. However, fundamental challenges persist with negative net income margins (-44.64%) and declining revenues from pandemic peak levels, offset by a robust $16.78 billion cash position and ongoing $1 billion share repurchase program.
The outlook balances promising oncology pipeline developments against near-term profitability challenges. Investment opportunity lies in BioNTech's cash-rich balance sheet and advancing cancer therapeutics, while risks include execution uncertainty in the therapeutic transition, manufacturing restructuring costs, and competitive pressure in the oncology space. The stock presents a high-risk, high-reward proposition for investors betting on successful pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
